REG - Proteome Sciences - Grant of Options and PDMR/director shareholdings

Proteome SciencesAnnouncement

12/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221012:nRSL5531Ca&default-theme=true

RNS Number : 5531C  Proteome Sciences PLC  12 October 2022

12 October 2022

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Grant of Options and PDMR/director shareholdings

 

Proteome Sciences announces the grant of options over new ordinary shares of
1p each in the Company ("Ordinary Shares") under the Company's share option
schemes ("Options"). A total of 3,000,000 Options were yesterday issued to two
directors of the Company.

 

Details of the Options granted to directors are outlined in the table below:

 

 Name of Director   Number of Options Granted  Total number of options now held
 Dr Ian Pike        1,500,000                  4,000,000
 Mr Richard Dennis  1,500,000                  4,000,000

 

The Options are exercisable at the closing price of the Company's Ordinary
Shares' yesterday, being 4.3 pence per Option.  For Dr Ian Pike and Mr
Richard Dennis, the Options will vest in three tranches as to 500,000 on 11
October 2023, 500,000 on 11 October 2024 and 500,000 on 11 October 2025.
Options have also been awarded to other employees totaling 2,520,000.  Each
Option is exercisable into one Ordinary Share and once vested, can be
exercised up until the 10th anniversary of yesterday's date.

 

The Options granted yesterday represent approximately 1.87 per cent of the
Company's current issued share capital. In total 20,534,000 Options are now
outstanding, representing approximately 6.96 per cent of the Company's current
issued share capital.

 

Further details and the information required in accordance with the
requirements of Article 19(3) of the Market Abuse Regulation No 596/2014 (as
retained and applicable in the UK pursuant to section 3 of the European Union
(Withdrawal) Act 2018) ("UK MAR") are set out at the end of this announcement.

 

For further information:

 

 Proteome Sciences plc                                         Tel: +44 (0)20 7043 2116

 Dr Mariola Soehngen, Chief Executive Officer

 Abdelghani Omari, Chief Financial Officer

 Dr Ian Pike, Chief Scientific Officer

 Allenby Capital Limited (AIM Nominated Adviser & Broker)      Tel: +44 (0) 20 3328 5656

 John Depasquale / Jeremy Porter

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of biological
activity, while analysis using Super-Depletion and TMTcalibrator™ provides
access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

 

The Company has its headquarters in Cobham, UK, with laboratory facilities in
Frankfurt, Germany.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

The below notification is made in accordance with the requirements of UK MAR.

 

 1.            Details of the person discharging managerial responsibilities/person closely
               associated
 a)            Name:                                                         Ian Pike
 2.            Reason for the notification
 a)            Position/status:                                              Chief Scientific Officer
 b)            Initial notification/Amendment:                               Initial Notification
 3.            Details of the issuer, emission allowance market participant, auction
               platform, auctioneer or auction monitor
 a)            Name:                                                         Proteome Sciences Plc
 b)            LEI:                                                          213800Q62ICXANKU2986
 4.            Details of the transaction(s): section to be repeated for (i) each type of
               instrument; (ii) each type of transaction; (iii) each date; and (iv) each
               place where transactions have been conducted
 a)            Description of the financial instrument, type of instrument:  Ordinary Shares of 1p nominal value

               Identification code:                                          GB0003104196
 b)            Nature of the transaction:                                    Grant of options under the Proteome Sciences plc 2011 Long Term Share
                                                                             Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc
 c)            Price(s) and volume(s):

Price(s)  Volume(s)
                                                                             £0.043    1,500,000
 d)            Aggregated information:                                       Single transaction as in c) above

Average Price  Volume(s)
               ·    Aggregated volume:                                       £0.043         1,500,000

               ·    Price:
 e)            Date of the transaction:                                      11 October 2022
 f)            Place of the transaction:                                     N/A

d)

Aggregated information:

·    Aggregated volume:

·    Price:

Single transaction as in c) above

 Average Price  Volume(s)
 £0.043         1,500,000

e)

Date of the transaction:

11 October 2022

f)

Place of the transaction:

N/A

 

 1.            Details of the person discharging managerial responsibilities/person closely
               associated
 a)            Name:                                                         Richard Dennis
 2.            Reason for the notification
 a)            Position/status:                                              Chief Commercial Officer
 b)            Initial notification/Amendment:                               Initial Notification
 3.            Details of the issuer, emission allowance market participant, auction
               platform, auctioneer or auction monitor
 a)            Name:                                                         Proteome Sciences Plc
 b)            LEI:                                                          213800Q62ICXANKU2986
 4.            Details of the transaction(s): section to be repeated for (i) each type of
               instrument; (ii) each type of transaction; (iii) each date; and (iv) each
               place where transactions have been conducted
 a)            Description of the financial instrument, type of instrument:  Ordinary Shares of 1p nominal value

               Identification code:                                          GB0003104196
 b)            Nature of the transaction:                                    Grant of options under the Proteome Sciences plc 2011 Long Term Share
                                                                             Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc
 c)            Price(s) and volume(s):

Price(s)  Volume(s)
                                                                             £0.043    1,500,000
 d)            Aggregated information:                                       Single transaction as in c) above

Average Price  Volume(s)
               ·    Aggregated volume:                                       £0.043         1,500,000

               Price:
 e)            Date of the transaction:                                      11 October 2022
 f)            Place of the transaction:                                     N/A

d)

Aggregated information:

·    Aggregated volume:

Price:

Single transaction as in c) above

 Average Price  Volume(s)
 £0.043         1,500,000

e)

Date of the transaction:

11 October 2022

f)

Place of the transaction:

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDFLFFLBLXFBV